Dr Dahiya on the FDA Approval of Liso-Cel for Relapsed/Refra

Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.

Related Keywords

Saurabh Dahiya , Stanford University School Of Medicine , Cell Therapy Division , Stanford University School , Cancer Cell Therapy , Risk Evaluation , Mitigation Strategy ,